# Title

 Food and Drugs. PART 349â€”OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE


# ID

 CFR-2018-title21-vol5.Pt. 349


# Structured Analysis Summary

| Type        | Values                                                                                                                                                    |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['maximum', 'more than', 'before', 'after', 'greater than', 'within', 'exceed']                                                                           |
| Duration    | ['72.0 hour', '4.0 hour']                                                                                                                                 |
| Condition   | ['subject to', 'when', 'if', 'unless', 'where']                                                                                                           |
| Entities    | ['Directions', 'Scope', 'Replace', 'Relieves', 'Permitted', 'Avoid', 'Naphazoline', 'Food', 'Applied', 'Indications', 'Warnings', 'Ophthalmic', 'Obtain'] |
| Date        | ['2018-05-12', '2018-05-10', '2018-05-14']                                                                                                                |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                   |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------|
| greater than  | An agent which exerts an osmotic gradient  greater than that present in body tissues and fluids, so                       |
| within        | the product consist of any of the following, within the established concentrations for each ingredient: (a) Cellulose     |
| within        | the product consists of one of the following, within the established concentration for each ingredient: (a) Ephedrine     |
| within        | are permitted provided each active ingredient is present within the established concentration, and the product is labeled |
| after         | Replace cap  after using.&#8221; (2) For ophthalmic drug products packaged in                                             |
| more than     | or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221;              |
| more than     | or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221;              |
| more than     | or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221;              |
| more than     | or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221;              |
| before        | and consult a doctor.&#8221; (2) &#8220;Ask a doctor before use if you have [in bold type] narrow                         |
| before        | Rinse cup with clean water immediately  before  each use.                                                                 |
| after         | Rinse cup with clean water  after  each use.                                                                              |
| exceed        | the directions for the combination product may not exceed any maximum dosage limits established for the individual        |
| maximum       | for the combination product may not exceed any maximum dosage limits established for the individual ingredients in        |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 72.0 hour  | In addition to the warnings in &#167;&#8201;349.50, the labeling of the product contains the following warnings under the heading &#8220;Warnings&#8221; for products containing any ingredient identified in &#167;&#8201;349.10:                                                                                                                                                                                                                |
|            |               (1) &#8220;If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221;                                                                                                                                                                                                                  |
|            |               (2) &#8220;If solution changes color or becomes cloudy, do not use.&#8221;                                                                                                                                                                                                                                                                                                                                                          |
|            |               (d) Directions.                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 72.0 hour  | In addition to the warnings in &#167;&#8201;349.50, the labeling of the product contains the following warnings under the heading &#8220;Warnings&#8221; for products containing any ingredient identified in &#167;&#8201;349.12:                                                                                                                                                                                                                |
|            |               (1) &#8220;If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221;                                                                                                                                                                                                                  |
|            |               (2) &#8220;If solution changes color or becomes cloudy, do not use.&#8221;                                                                                                                                                                                                                                                                                                                                                          |
|            |               (d) Directions.                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 72.0 hour  | In addition to the warnings in &#167;&#8201;349.50, the labeling of the product contains the following warnings under the heading &#8220;Warnings&#8221; for products containing any ingredient identified in &#167;&#8201;349.14: &#8220;If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221; |
|            |               (d) Directions.                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4.0 hour   | The labeling of the product contains the following information under the heading &#8220;Directions&#8221;: Instill 1 or 2 drops in the affected eye(s) every 3 or 4 hours, or as directed by a doctor.                                                                                                                                                                                                                                            |
| 72.0 hour  | In addition to the warnings in &#167;&#8201;349.50, the labeling of the product contains the following warnings under the heading &#8220;Warnings&#8221; for products containing any ingredient identified in &#167;&#8201;349.18:                                                                                                                                                                                                                |
|            |               (1) &#8220;If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.&#8221;                                                                                                                                                                                                                  |
|            |               (2) &#8220;Ask a doctor before use if you have [in bold type] narrow angle glaucoma.&#8221;                                                                                                                                                                                                                                                                                                                                         |
|            |               (3) &#8220;Overuse of this product may produce increased redness of the eye.&#8221;                                                                                                                                                                                                                                                                                                                                                 |
|            |               (4) &#8220;If solution changes color or becomes cloudy, do not use.&#8221;                                                                                                                                                                                                                                                                                                                                                          |
|            |               (5) &#8220;When using this product [in bold type] pupils may become enlarged temporarily.&#8221;                                                                                                                                                                                                                                                                                                                                    |
|            |               (d) Directions.                                                                                                                                                                                                                                                                                                                                                                                                                     |


## Condition

| Condition   | Context                                                                                                                                       |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| if          | as safe and effective and is not misbranded if it meets each of the conditions in this                                                        |
| unless      | Regulations are to chapter I of title 21 unless  otherwise noted.                                                                             |
| when        | A pharmacologic agent which,  when applied topically to the mucous membranes of the                                                           |
| when        | (b) Dextran 70, 0.1 percent  when used with another polymeric demulcent agent in this                                                         |
| where       | that the resulting information is clear and understandable. where                                                                             |
| subject to  | may also be used, as provided in &#167;&#8201;330.1(c)(2), subject to the provisions of section 502 of the act                                |
| if          | Do not use this product  if you are sensitive to&#8221; (select one of the                                                                    |
| if          | product contains the established name of the drug, if  any, and ident                                                                         |
| if          | heading &#8220;Warnings&#8221; for products containing any ingredient ident if ied in &#167;&#8201;349.10: (1) &#8220;If you experience eye   |
| if          | product contains the established name of the drug(s), if  any, and ident                                                                      |
| if          | heading &#8220;Warnings&#8221; for products containing any ingredient ident if ied in &#167;&#8201;349.12: (1) &#8220;If you experience eye   |
| if          | product contains the established name of the drug(s), if  any, and ident                                                                      |
| if          | heading &#8220;Warnings&#8221; for products containing any ingredient ident if ied in &#167;&#8201;349.14: &#8220;If you experience eye pain, |
| if          | product contains the established name of the drug, if  any, and ident                                                                         |
| if          | continued redness or irritation of the eye, or if the condition worsens or persists, consult a doctor.&#8221;                                 |
| if          | product contains the established name of the drug(s), if  any, and ident                                                                      |
| if          | heading &#8220;Warnings&#8221; for products containing any ingredient ident if ied in &#167;&#8201;349.18: (1) &#8220;If you experience eye   |
| if          | heading &#8220;Warnings&#8221; for products containing any ingredient ident if ied in &#167;&#8201;349.18: (1) &#8220;If you experience eye   |
| if          | continued redness or irritation of the eye, or if the condition worsens or persists, consult a doctor.&#8221;                                 |


## Entities

| Entities    | Context                                                                                                                     |
|:------------|:----------------------------------------------------------------------------------------------------------------------------|
| Food        | Food  and Drugs.                                                                                                            |
| Scope       | Scope .                                                                                                                     |
| Applied     | Applied topically to the eye, a hypertonicity agent creates                                                                 |
| Ophthalmic  | Ophthalmic  astringent.                                                                                                     |
| Ophthalmic  | Ophthalmic  demulcents.                                                                                                     |
| Ophthalmic  | Ophthalmic  emollients.                                                                                                     |
| Ophthalmic  | Ophthalmic  hypertonicity agent.                                                                                            |
| Ophthalmic  | Ophthalmic  vasoconstrictors.                                                                                               |
| Naphazoline | (b)  Naphazoline  hydrochloride, 0.01 to 0.03 percent.                                                                      |
| Permitted   | Permitted  combinations of active ingredients.                                                                              |
| Replace     | Replace cap after using.&#8221; (2) For ophthalmic drug products                                                            |
| Indications | of the product states, under the heading &#8220; Indications ,&#8221; the following phrase: &#8220;For the temporary relief |
| Indications | of the product states, under the heading &#8220; Indications ,&#8221; one or more of the following phrases:                 |
| Indications | of the product states, under the heading &#8220; Indications ,&#8221; one or more of the following phrases:                 |
| Indications | of the product states, under the heading &#8220; Indications ,&#8221; the following phrase: &#8220;For the temporary relief |
| Indications | of the product states, under the heading &#8220; Indications ,&#8221; the following phrase: &#8220;Relieves redness of the  |
| Relieves    | under the heading &#8220;Indications,&#8221; the following phrase: &#8220; Relieves redness of the eye due to minor eye     |
| Indications | of the product states, under the heading &#8220; Indications ,&#8221; one of the following phrases: (1) &#8220;For&#8221;   |
| Obtain      | worsens or persists, consult a doctor.&#8221; (2) &#8220; Obtain immediate medical treatment for all open wounds in         |
| Avoid       | Avoid  contamination of rim and inside surfaces of cup.                                                                     |
| Indications | of the product states, under the heading &#8220; Indications ,&#8221; the indication(s) for each ingredient in the          |
| Warnings    | of the product states, under the heading &#8220; Warnings ,&#8221; the warning(s) for each ingredient in the                |
| Directions  | of the product states, under the heading &#8220; Directions ,&#8221; directions that conform to the directions established  |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-05-10 | (a) Any single ophthalmic astringent active ingredient identified in &#167;&#8201;349.10 may be combined with any single ophthalmic vasoconstrictor active ingredient identified in &#167;&#8201;349.18.                                                                                                                                                       |
| 2018-05-12 | (b) Any two or three ophthalmic demulcent active ingredients identified in &#167;&#8201;349.12 may be combined.                                                                                                                                                                                                                                                |
| 2018-05-10 | (d) Any single ophthalmic astringent active ingredient identified in &#167;&#8201;349.10 may be combined with any single ophthalmic vasoconstrictor active ingredient identified in &#167;&#8201;349.18 and any single ophthalmic demulcent identified in &#167;&#8201;349.12 or ophthalmic demulcent combination identified in paragraph (b) of this section. |
| 2018-05-14 | (e) Any two or more emollient active ingredients identified in &#167;&#8201;349.14 may be combined as necessary to give the product proper consistency for application to the eye.                                                                                                                                                                             |


